94Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Mexico
Neuroscience Intelligence
Mexico neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #32 of 50 · Data maturity A · Research score 33.7 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
20Recruiting trials
36Publications
31Institutions
Executive interpretation
Mexico ranks #32 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC86 recruiting
Hoffmann-La Roche82 recruiting
Pfizer70 recruiting
UCB Pharma50 recruiting
Eli Lilly and Company50 recruiting
Boehringer Ingelheim40 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.40 recruiting
Washington University School of Medicine33 recruiting
Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente20 recruiting
Instituto Neurociencia Del Dolor20 recruiting
Disease activity
Epilepsy19trials
Alzheimers14trials
Parkinsons14trials
Depression7trials
Schizophrenia7trials
Other Neurology5trials
Multiple Sclerosis5trials
Migraine Headache3trials
Autism3trials
Anxiety2trials
Research institutions
Centro de Investigación y de Estudios Avanzados del Instituto Politécnico NacionalOpenAlexlinked institution
Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránOpenAlexlinked institution
Centro Médico ABCOpenAlexlinked institution
National Institute of Genomic MedicineOpenAlexlinked institution
Hospital Médica SurOpenAlexlinked institution
Instituto Nacional de PerinatologíaOpenAlexlinked institution
Centro de Investigaciones en OpticaOpenAlexlinked institution
Hospital General de MéxicoOpenAlexlinked institution
Instituto Nacional de Psiquiatría Ramón de la Fuente MuñizOpenAlexlinked institution
Instituto Nacional de PediatriaOpenAlexlinked institution
Clinical evidence trail
NCT07276555Efficacy and Safety of Functional Neurogenesis Stimulation Therapy in Children With Autism Spectrum Disorder (ASD)NOT_YET_RECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT07174310A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseaseRECRUITING
NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06563895Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRECRUITING
NCT06504394A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)ACTIVE_NOT_RECRUITING
NCT06290128A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not WorkACTIVE_NOT_RECRUITING
NCT06170788Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)RECRUITING
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RECRUITING
Research evidence trail
PUBMEDAssessing progesterone receptor modulation in glioblastoma: from in vitro and animal model to a human pilot protocol.2026-12-31
PUBMEDLong-term outcomes of microvascular decompression vs neurotomy for glossopharyngeal neuralgia: a multicenter clinimetric study.2026-12-01
PUBMEDClinical correlates of childhood- and adolescent-onset depression in a Mexican pediatric psychiatric cohort.2026-12-01
PUBMEDTransient neonatal hypoglycemia and the developing brain: Associations, mechanisms, and clinical implications.2026-11-01
PUBMEDSleep stage-dependent distribution of interictal epileptiform discharges in epilepsy: A systematic review.2026-11-01
PUBMEDVortioxetine transiently alters basal locomotor activity but does not produce sedation in rats.2026-10-15
PUBMEDGunshot-induced carotid artery injury: exploring other determined aetiologies of stroke.2026-10-01
PUBMEDIsolation of adipose-derived mesenchymal stromal cells expressing soluble forms of GAS1 and PTEN for experimental cell therapy for glioblastoma.2026-10-01
PUBMEDClinical and Cytogenomic Characterization of Three Patients With Distal 1q43q44 Deletion: Twin Sisters With a de novo Deletion and a Patient With der(1)t(1;21)(q43;q22.3)mat.2026-10-01
PUBMEDEpidemiology and neurological profiling of vertebral tumors in Mexico: a five-year review from a tertiary referral center.2026-10-01
PUBMEDExperience, challenges, and regional integration of the National Dementia Biobank (Mexico) and the National Brain Bank-UNPHU (Dominican Republic).2026-10-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.